Advertisement

Topics

J&J's apalutamide scores snap FDA approval in castration-resistant prostate cancer subgroup

05:11 EST 15 Feb 2018 | Pharmafile

Johnson & Johnson has announced that its androgen receptor inhibitor apalutamide, now branded as Erleada, has received approval from the FDA for the treatment of non-metastatic castration-resistant prostate cancer that continues to grow despite the administration of hormone therapy, just a week after it made public strong new data in the same indication.

read more

Original Article: J&J's apalutamide scores snap FDA approval in castration-resistant prostate cancer subgroup

NEXT ARTICLE

More From BioPortfolio on "J&J's apalutamide scores snap FDA approval in castration-resistant prostate cancer subgroup"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...